Document is current
Any future updates will be listed below
-
Authors
Jochem, Marco https://orcid.org/0000-0003-4982-1953
Cobbold, Simon A. https://orcid.org/0000-0002-9927-8998
Goodman, Craig A.
Kueng, Catharina
Cerra, Anthony
Fielden, Laura F.
Kim, Man Lyang
Schenk, Philipp
Agarwal, Ria
Wang, Xiangyi S. https://orcid.org/0000-0002-1235-6616
Scutts, Simon R. https://orcid.org/0000-0002-2670-3682
Pandos, Michael
Tang, Lin
Hermanns, Thomas https://orcid.org/0000-0001-5350-7479
Devine, Shane M. https://orcid.org/0000-0001-8727-7392
Brzozowski, Martin
Shibata, Yuri
Geoghegan, Niall D. https://orcid.org/0000-0001-9884-0769
McLean, Catriona A.
Lechtenberg, Bernhard C. https://orcid.org/0000-0002-5674-6894
Hofmann, Kay https://orcid.org/0000-0002-2289-9083
Gregorevic, Paul https://orcid.org/0000-0002-7418-8945
Komander, David https://orcid.org/0000-0002-8092-4320
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 14 April 2026
First Online: 22 April 2026
Competing interests
: D.K. is founder, shareholder and scientific advisory board member of Entact Bio and Proxima Bio, and founder and scientific advisory board member of Ternarx. B.C.L. is founder and scientific lead at Ternarx. The Walter and Eliza Hall Institute has filed a provisional patent (AU) 2025905184 with D.K., S.A.C. and M.J. as inventors in relation to modulating glycogen via induced ubiquitination. The other authors declare no competing interests.
